| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Sunitinib in patients with metastatic renal cell carcinoma.
|
JAMA
|
2006
|
11.33
|
|
2
|
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
|
J Clin Oncol
|
2005
|
4.64
|
|
3
|
Sunitinib efficacy against advanced renal cell carcinoma.
|
J Urol
|
2007
|
3.14
|
|
4
|
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.
|
J Clin Oncol
|
2008
|
2.77
|
|
5
|
Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.
|
J Clin Oncol
|
2007
|
2.57
|
|
6
|
NCCN clinical practice guidelines in oncology: kidney cancer.
|
J Natl Compr Canc Netw
|
2009
|
2.40
|
|
7
|
NCCN clinical practice guidelines in oncology: testicular cancer.
|
J Natl Compr Canc Netw
|
2009
|
1.86
|
|
8
|
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.
|
J Clin Oncol
|
2010
|
1.68
|
|
9
|
Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
|
Biol Blood Marrow Transplant
|
2006
|
1.63
|
|
10
|
Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.
|
Proc Natl Acad Sci U S A
|
2012
|
1.58
|
|
11
|
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.
|
J Clin Oncol
|
2003
|
1.49
|
|
12
|
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.
|
J Immunother
|
2013
|
1.48
|
|
13
|
Testicular cancer.
|
J Natl Compr Canc Netw
|
2012
|
1.11
|
|
14
|
Kidney cancer.
|
J Natl Compr Canc Netw
|
2011
|
1.06
|
|
15
|
Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin.
|
Clin Cancer Res
|
2011
|
1.03
|
|
16
|
Kidney cancer, version 2.2014.
|
J Natl Compr Canc Netw
|
2014
|
0.98
|
|
17
|
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.
|
J Natl Compr Canc Netw
|
2011
|
0.94
|
|
18
|
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
|
J Clin Oncol
|
2009
|
0.94
|
|
19
|
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
|
PLoS One
|
2012
|
0.92
|
|
20
|
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
|
Cancer
|
2008
|
0.92
|
|
21
|
A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
|
Invest New Drugs
|
2010
|
0.90
|
|
22
|
Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction.
|
Cancer
|
2004
|
0.82
|
|
23
|
Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases.
|
Am Soc Clin Oncol Educ Book
|
2013
|
0.81
|
|
24
|
State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer.
|
Cancer
|
2008
|
0.80
|
|
25
|
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study.
|
Cancer Chemother Pharmacol
|
2009
|
0.80
|
|
26
|
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.
|
Int J Clin Oncol
|
2011
|
0.79
|
|
27
|
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery.
|
J Clin Oncol
|
2010
|
0.79
|
|
28
|
Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies.
|
Cancer
|
2006
|
0.79
|
|
29
|
Multidisciplinary approach to brain metastasis from melanoma: the emerging role of systemic therapies.
|
Am Soc Clin Oncol Educ Book
|
2013
|
0.77
|
|
30
|
Inside life of melanoma cell signaling, molecular insights, and therapeutic targets.
|
Curr Oncol Rep
|
2009
|
0.77
|
|
31
|
Testicular cancer. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.76
|
|
32
|
An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer.
|
Cancer
|
2012
|
0.75
|
|
33
|
Kidney cancer. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2006
|
0.75
|
|
34
|
The significance of solid tumor stem cells in melanoma: Part 1.
|
Curr Oncol Rep
|
2008
|
0.75
|
|
35
|
The significance of solid tumor stem cells in melanoma: Part 2.
|
Curr Oncol Rep
|
2008
|
0.75
|
|
36
|
Kidney cancer. Clinical practice guidelines.
|
J Natl Compr Canc Netw
|
2005
|
0.75
|
|
37
|
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study.
|
J Immunother
|
2007
|
0.75
|
|
38
|
Testicular cancer. Clinical practice guidelines.
|
J Natl Compr Canc Netw
|
2005
|
0.75
|